Evidence map›Paper›PMID 20130076›Full record

ArticleThe Journal of clinical endocrinology and metabolism2010

LMNA mutations, skeletal muscle lipid metabolism, and insulin resistance.

Michael Boschmann, Stefan Engeli, Cedric Moro, Angelika Luedtke, Frauke Adams, Kerstin Gorzelniak, Gabriele Rahn, Anja Mähler, Kerstin Dobberstein, Antje Krüger and 6 more

Erratum issuedOpen access · bronzeAbstract read
In one paragraph

Article in The Journal of clinical endocrinology and metabolism, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 29 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 2 pooled it
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 2 syntheses or guidelines pooled it, 53 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

  • Erratum issued
5 · Who and what money

Authors and funding

16 authors at 6 institutions in 2 countries.

Michael BoschmannFranz-Volhard Clinical Research Center at the Experimental and Clinical Research Center, University Hospital Charite Campus Buch and HELIOS Klinikum-Berlin, 13125 Berlin, Germany. michael.boschmann@charite.de
Stefan Engeli
Cedric Moro
Angelika Luedtke
Frauke Adams
Kerstin Gorzelniak
Gabriele Rahn
Anja Mähler
Kerstin Dobberstein
Antje Krüger
Saskia Schmidt
Simone Spuler
Friedrich C Luft
Steven R Smith
Hartmut H-J Schmidt
Jens Jordan
Charité - Universitätsmedizin Berlin · DEHelios Hospital Berlin-Buch · DEMedizinische Hochschule Hannover · DEPennington Biomedical Research Center · USColumbia University · USUniversity of Münster · DE

Funding

Research BaseP30DK072476 · NIDDK · LSU PENNINGTON BIOMEDICAL RESEARCH CTR · PI Peter Todd Katzmarzyk · 2005 to 2026
$26.5M
Skeletal Muscle Mitochondrial Adaptations to a Two-Year Caloric RestictionR01AG030226 · NIA · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI SMITH, STEVEN RICHARD · 2008 to 2012
$1.6M
NIA NIH HHS R01AG030226NIDDK NIH HHS P30 DK072476NIDDK NIH HHS P30-DK072476
6 · The paper itself

Abstract

contextType 2 familial partial lipodystrophy (FPLD) is an autosomal-dominant lamin A/C-related disease associated with exercise intolerance, muscular pain, and insulin resistance. The symptoms may all be explained by defective metabolism; however, metabolism at the tissue level has not been investigated.

objectiveWe hypothesized that in FPLD, insulin resistance and impaired aerobic exercise capacity are explained by a common underlying mechanism, presumably a muscular metabolic defect. PATIENTS AND

methodsCarbohydrate and lipid metabolism was studied on 10 FPLD patients, one patient with limb-girdle muscular dystrophy (LGMD1B, a different lamin A/C disease), and 10 healthy control subjects before and during an oral glucose tolerance test by indirect calorimetry and im microdialysis. Muscle biopsies were taken for in vitro studies.

resultsWe observed marked increased skeletal muscle fatty acid beta-oxidation rate in vitro and in vivo, even after glucose ingestion in FPLD patients. However, fatty acid oxidation was largely incomplete and accompanied by increased ketogenesis. The lipid oxidation abnormality was associated with impaired glucose disposition through reduction in glucose oxidation, rather than decreased cellular glucose uptake. A microarray showed down-regulation of complex I respiratory chain, glycolysis, and nuclear transport genes. Although not overtly insulin resistant, the LGMD1B patient showed similar metabolic derangements as the FPLD patients.

conclusionsOur study suggests imbalance between lipid oxidation and oxidative glucose metabolism in FPLD and LGMD1B patients. The observation suggests an intrinsic defect in skeletal muscle metabolism due to lamin A/C dysfunction. The metabolic FPLD phenotype likely results from this intrinsic defect combined with lipodystrophic "lipid pressure" due to decreased adipose tissue lipid storage capacity.

Indexed as

AdultBlood GlucoseCarnitineCells, CulturedEnergy MetabolismFemaleGlycogenHumansInsulinInsulin ResistanceLamin Type ALipid MetabolismLipodystrophy, Familial PartialMaleMiddle AgedMuscle Fibers, SkeletalacylcarnitineBlood GlucoseCarnitineGlycogenInsulinLamin Type ALMNA protein, human

Identifiers

PMID20130076
PMCPMC2853996
OpenAlexW2033669568

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.